>>10566107 lb

When Q drops a name like Ezra Cohen-Watnick

Is he dropping a hint about this person?

Or is suggesting that the initials ECW are important to dig?

Check the previous message linked above…

A revolutionary new way to generate electricity

But wait!

What would you use lots of cheap electricity for?

Maybe for Electronic Control Weapons? ECWs?

Arrogance leads to losing battles

And defeat in wars.

Always be learning

Always be thinking

Always be analyzing

And never forget why we fight

It's not for freedom or liberty or the Rule of Law

Those are just means to an end.

We fight for a BETTER FUTURE

The Best Is Yet To Come!!!

Vitamin D, First clinical trial

Please share this video around, this message needs to get out there, thank you, John

https://www.healthline.com/nutrition/how-much-vitamin-d-to-take#How-Common-Is-Vitamin-D-Deficiency

About 42% of the US population is vitamin D deficient

82% in black people

70% in Hispanics

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results, (JAMA Open, 3rd September, Chicago)

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2770157/meltzer_2020_oi_200688_1598473478.89934.pdf

Cohort study of 489

Patients who had a vitamin D level measured in the year before COVID-19

testing

Relative risk of testing positive for COVID-19 was 1.77 times

First clinical trial on vitamin D and COVID

Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study" (Spain, Journal of steroid biochemistry and molecular biology)

https://www.sciencedirect.com/science/article/pii/S0960076020302764

Objective

Vitamin D decreases Acute Respiratory Distress Syndrome

Effect of calcifediol treatment

Calcifediol can rapidly increase serum 25OHD concentration

25-hydroxyvitamin D

Intensive Care Unit Admission and Mortality

Spanish patients hospitalized for COVID-19.

Design

Parallel pilot, randomized, double-masked clinical trial

Setting

Reina Sofia University Hospital, Córdoba, Spain

Participants

76 consecutive patients hospitalized with COVID-19 infection

Clinical picture of acute respiratory infection

Confirmed by a radiographic pattern of viral pneumonia

Positive SARS-CoV-2 PCR

Procedures

All hospitalized patients received as best available therapy

Hydroxychloroquine and azithromycin

Allocated at a 2 calcifediol:1

Oral calcifediol (0.532 mg), or not

Oral calcifediol (0.266 mg) on day 3 and 7

Then weekly until discharge

End points, ICU admission and deaths.

Results

50 patients treated with calcifediol

One required admission to the ICU (2%),

Of 26 untreated patients, 13 required admission (50%)

p  less than 0.001

Of the patients treated with calcifediol, none died, and all were discharged, without complications

Of the patients not treated, 2 died

Conclusion

Calcifediol seems to be able to reduce severity of the disease

Larger trials with groups properly matched will be required to show a definitive answer

Rationale, activation of the vitamin D receptor (VDR) signalling pathway

Reduced ARDS

Cytokine/chemokine storm

Regulating the renin angiotensin system

Modulating neutrophil activity

Maintaining the integrity of the pulmonary epithelial barrier

Stimulating epithelial repair

Tapering down the increased coagulability

Ventilate

Don't abdicate

Dilute that virus

So you stay great

Ventilate

Don't complicate,

Complain or whine

You'll acclimate

Contemplate

When you congregate

Does the air here circulate

Instigate, Nominate

Educate, Motivate

I hope this message will resonate

That when we populate

Instead of isolate

Ventilate

Don't abdicate

Dilute that virus

So you stay great

>>10566590

And here is Dr. Mercola's guidance on building up the Vitamin D reserves in your body

As well as a study from Indonesia

And finally, a PDF of the Meltzer study from JAMA mentioned in the video.

Patent-Free Way to Make and Control Large Scale EVOs

EVOs are Exotic Vacuum Objects found in plasmas used in fusion reactors

The Plasmak paper can be downloaded from Here:

https://web.archive.org/web/20120712235535/http://www.prometheus2.net/ICC_2002_POSTER.pdf

There is also much info in the PLASMAK patent US5041760

"Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study"

https://www.sciencedirect.com/science/article/pii/S0960076020302764

Abstract

Objective

The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly increase serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.

Design

parallel pilot randomized open label, double-masked clinical trial.

Setting

university hospital setting (Reina Sofia University Hospital, Córdoba Spain.)

Participants

76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score 1).

Procedures

All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 hours on the first day, and 200 mg every 12 hours for the following 5 days), azithromycin (500 mg orally for 5 days. Eligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not. Patients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission and deaths.

Results

Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50%) p value X2 Fischer test p < 0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95%CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95%CI: 0.003-0.25). Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.

Conclusion

Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.

Full PDF article is attached